Axsome Q2 2020 Earnings Report
Key Takeaways
Axsome Therapeutics reported its Q2 2020 financial results, highlighting progress in its CNS pipeline with multiple FDA Breakthrough Therapy designations and advancements towards NDA submissions for AXS-05 and AXS-07. The company is on track with clinical trials and anticipates key milestones in the near term.
Two NDA submissions for AXS-05 in MDD and AXS-07 in migraine are on track for Q4 2020.
Enrollment was completed for Phase 3 long-term safety trials of AXS-05 in MDD and AXS-07 in migraine.
Results from three Phase 2 open-label efficacy trials of AXS-05 in TRD, antidepressant unresponsive MDD, and suicidal ideation are expected in Q4 2020.
Phase 3 trials for AXS-05 in Alzheimer’s disease agitation and AXS-12 in narcolepsy are on track for Q4 2020.
Axsome
Axsome
Forward Guidance
Axsome believes that its cash at June 30, 2020 will be sufficient to fund the Company’s anticipated operations, based on its current operating plans, for at least two years.